https://www.precede.bio https://www.precede.bio/news/aacr25 https://www.precede.bio/news/aacrlbx24 https://www.precede.bio/news/asco25 https://www.precede.bio/news/data-demonstrating-precede-biosciences-ability-to-determine-her2-status-from-1ml-of-plasma-to-be-presented-at-the-2023-san-antonio-breast-cancer-symposium https://www.precede.bio/news/data-presented-at-sabcs-demonstrate-the-significant-promise-of-precede-biosciences-novel-liquid-biopsy-platform-to-define-her2-and-er-status-in-patients-with-advanced-breast-cancer https://www.precede.bio/news/ectrims24-ms https://www.precede.bio/news/esmo24-psma https://www.precede.bio/news/esmo25 https://www.precede.bio/news/precede-bio-insight-launch https://www.precede.bio/news/precede-biosciences-announces-first-scientific-data-from-its-liquid-biopsy-platform-to-be-presented-as-an-oral-presentation-at-esmo-2023 https://www.precede.bio/news/precede-biosciences-emerges-from-stealth-to-dramatically-impact-precision-medicine-with-a-first-in-class-liquid-biopsy-platform https://www.precede.bio/news/precede-biosciences-presents-new-data-at-asco-2024-demonstrating-accurate-her2-status-detection-across-multiple-cancers-and-the-ability-to-quantify-er-pathway-activation-in-breast-cancer-from-a-simple-blood-test https://www.precede.bio/news/precede-biosciences-to-present-scientific-data-for-its-comprehensive-epigenomic-liquid-biopsy-platform-at-aacr-2024 https://www.precede.bio/news/precede-biosciences-unveils-groundbreaking-clinical-data-for-its-pioneering-liquid-biopsy-platform-at-esmo-2023-and-simultaneously-publishes-in-nature-medicine https://www.precede.bio/news/sabcs2024 https://www.precede.bio/news/seriesb-financing https://www.precede.bio/team-member-types/bod https://www.precede.bio/team-member-types/leadership https://www.precede.bio/team-member-types/sab https://www.precede.bio/team-member-types/team https://www.precede.bio/legal-documents/cookie-notice https://www.precede.bio/legal-documents/privacy-policy https://www.precede.bio/publications/cell-reports-june2024-epigenomicsignaturesrcc https://www.precede.bio/publications/clinical-cancer-research-june-2024-advanced-egfr-mutant-lung-adenocarcinoma https://www.precede.bio/publications/nature-medicine-article https://www.precede.bio/presentations/2023-esmo-presentation https://www.precede.bio/presentations/2023-sabcs-poster-liquid-biopsy-determination-of-her2-status-in-breast-cancer-results-from-a-novel-epigenomic-platform https://www.precede.bio/presentations/2023-sabcs-presentation-liquid-biopsy-determination-of-her2-status-in-breast-cancer-results-from-a-novel-epigenomic-platform https://www.precede.bio/presentations/2024-aacr-comprehensive-epigenomic-profiling-from-plasma-to-inform-therapy-selection-a-proof-of-concept-study-in-cancer https://www.precede.bio/presentations/2024-aacr-lbx-platform-presentation https://www.precede.bio/presentations/2024-aacr-lbx-psma-poster https://www.precede.bio/presentations/2024-aacr-poster-a-novel-epigenomic-profiling-assay-reveals-disease-biology-and-therapeutic-targets-in-gastro-esophageal-cancer-from-1ml-of-plasma https://www.precede.bio/presentations/2024-aacr-poster-novel-liquid-biopsy-based-determination-of-lung-cancer-histology-using-a-comprehensive-epigenomic-platform-reveals-enhancer-activity-as-a-key-determinant-for-accurate-classification https://www.precede.bio/presentations/2024-sabcs-poster https://www.precede.bio/presentations/2025ascogu https://www.precede.bio/presentations/2025esmo-sclc-poster https://www.precede.bio/presentations/2026-aacr-poster-nepc https://www.precede.bio/presentations/2026-aacr-poster-perdi-dfci https://www.precede.bio/presentations/2026-aacr-poster-perdi-genentech https://www.precede.bio/presentations/aacr25-poster https://www.precede.bio/presentations/asco2024-er https://www.precede.bio/presentations/asco2024-her2 https://www.precede.bio/presentations/asco25-mbc-poster https://www.precede.bio/presentations/asco25-mcrpc-poster https://www.precede.bio/presentations/ectrims2024-ms https://www.precede.bio/presentations/esmo24-psma